Welcome to Naia

We fund and develop companies that address regional and global unmet medical needs, utilizing our international base of operations to develop therapeutics better, faster, at lower cost and in proximity to target markets.

Our Values

Nai`a is the Hawaiian name for spinner dolphins – renowned for their acrobatic behavior and symbolizing energy, creativity and positivity.  Their habitat is worldwide and they are known to be extremely social, forming collaborations amongst themselves and, in Hawaii, even with local fishermen.

We chose the name Naia because we are building an international organization to bring creative solutions to worldwide health issues.  We rely on a growing network of collaborations, starting with our first investor, Pharco Pharmaceuticals of Alexandria, Egypt, and our renowned international Advisory Board.

We admire the spirit, energy and collaborative creativity of the Nai`a.  We are building our company around the same qualities.

Our Aim

Our aim is simple: To build globally focused biotechnology companies which employ innovative drug development and business practices, to deliver therapeutic products in the most efficient and cost-effective manner.

The vision, experience and dedication of our people is the foundation upon which we have built our organization and continues to drive our development. A powerful combination of cutting-edge clinical excellence and innovative business strategy is what allows us to continually meet and exceed expectations at every level.

Our focus is on addressing unmet medical needs. Our products are innovative and will, subject to successful development and approval, provide significant benefits to patients worldwide.

Our People

Naia’s management team and founders have extensive experience starting, building and managing companies globally, including the US, Europe, Middle East, Asia and South America.

Together, their backgrounds include academia, pharma, biotech, and diagnostics in a variety of leadership roles.

This experience, along with a shared vision for creating a nimble, flexible model for global drug development is an essential ingredient in Naia’s success.

H Daniel Perez MD

H Daniel Perez MD
Co-Founder, CEO and Chairman

During his twenty-four years in the pharmaceutical industry, Dr Perez has developed wide-ranging experience driving R&D operations, clinical trials, collaborations, licensing deals, spin-outs and acquisitions. He has published extensively and has been elected to multiple scientific societies and Boards.
Read More

H Daniel Perez MD co-founded Naia Rare Diseases and currently serves as Chairman and Chief Executive Officer.

Prior to that, he was a venture partner at Bay City Capital. Earlier in his career, he was president and chief executive officer of Berlex Biosciences (the U.S. arm of Schering AG). He led R&D efforts in the United States, Berlin and Kobe, initiated multiple clinical trials, and oversaw the execution of numerous collaborations, licensing deals, spin-outs and acquisitions until he left the company upon its acquisition by Bayer. Dr. Perez has published extensively and has been elected to multiple scientific societies and nominated to the National Academy of Sciences.

Dr. Perez serves on the Board of Directors of Presidio Pharmaceuticals and Celtaxsys, on the Scientific Advisory Board of Cardium, on the Investment Board of Glaxo GSK, China and on the President’s Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). Previously, he was a member of the Board of Directors of BayBio, Cleveland Biolabs and Hyperion Therapeutics.

He received his medical degree in Buenos Aires, Argentina. He completed his medical training at Beth Israel-Mount Sinai in New York and a fellowship in rheumatology and immunology at New York University. He served on the faculty at New York University as an assistant professor of medicine and at UCSF as a professor of medicine before joining the pharmaceutical industry.

Mark Bagnall

Mark Bagnall
Co-Founder, CFO and COO

Mr Bagnall has held c-suite positions in public and private biotechnology companies for more than 20 years. During that time, he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings and negotiated numerous licensing agreements.
Read More

Mark Bagnall co-founded Naia Rare Diseases and currently serves as Chief Financial Officer, Chief Operating Officer and a Director.

He has held senior management positions in public and private biotechnology companies for more than 20 years. During that time he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings, and negotiated numerous licensing agreements.

Prior to founding Naia, he served as president, chief executive officer and a member of the Board of Directors of GenturaDx until its successful sale to Luminex Corporation. GenturaDx was a BVI-based molecular diagnostics company with operations in Shanghai, China and the San Francisco Bay Area.  Before joining GenturaDx, Mr Bagnall was executive vice president and a member of the Board of ADVENTRX Pharmaceuticals. Prior to ADVENTRX, he was senior vice president at Metabolex, Inc., where he raised more than $100 million Before Metabolex, Mr Bagnall was chief financial officer of several public and private biotechnology companies and was responsible for many public and private financings, mergers and licensing transactions.

Mr Bagnall was one of the founders the Association of Bioscience Financial Officers, an international organization of life science CFOs. He serves on the Board of Directors of Ativa Medical Corporation is an advisor to the Board of Fluoresentric, Inc. Previously, he served on the Boards of ADVENTRX Pharmaceuticals and VIA Pharmaceuticals. He is a CPA and started his career in the high technology/biotechnology practice of Ernst & Young.

Board of Directors

Dr Sherine Helmy

Dr Sherine Helmy

Co-Founder and investor
Naia Board of Directors

 

Dr Sherine Helmy has 30 years of experience in the pharmaceutical industry and is the chief executive officer of Pharco Pharmaceuticals, in addition to serving on various other Boards, both commercial and academic.

Read More

“As a regionally focused pharmaceutical company, a major challenge we face is bringing innovative medicines to patients and healthcare providers that are both appropriate and brought forward in the right time. Knowing the individual backgrounds of the [Naia] management team, combined with the approach of the business model, it was immediately evident the right components where in place that could help Pharco to make a difference in emerging markets such as Egypt.”

Sherine Helmy, Pharm Bsc MBA DBA, has 30 years of experience in the pharmaceutical industry and is the chief executive officer of Pharco Pharmaceuticals.

He is also vice president and managing director of Baterjee Pharmaceuticals, vice president and managing director of Beovita Gmbh in Germany, vice president of Hassan Abbas Helmy Institute for Social Affairs, and a consultant to TOANO in Belgium.

Dr Helmy is involved with a number of organizations related to the pharmaceutical industry and economic growth in Egypt. He serves as a board member of Alexandria University, the Egyptian Japanese University of Technology (EJUST), the National Authority for Quality Assurance and Accreditation of Education (NAQAAE), the Egyptian Accreditation Council (EGAC), the Supreme Council for Culture- Committee of Management Sciences, the New Borg El Arab City Culture Palace, and a founding member of North Coast University (NCU).

He earned a BSc in pharmacy from Alexandria University, an MBA from the Arab Academy for Science & Technology (AAST)/Central Michigan University, and a Doctorate of Business Administration (DBA) from AAST.

Dr Omar Haffar PhD

Dr Omar Haffar PhD

Naia Board of Directors

 

Dr Omar Haffar PhD is a cell biologist with 28 years of experience in the biotechnology industry and is the president and chief executive officer of Eos Biosciences Inc, in addition to serving on the Naia Board of Directors.

Read More

“One of the challenges I have seen companies face in developing drugs for emerging markets is creating a solid pipeline of promising products that directly address the unique needs of patients, and that are priced appropriately for the health systems in those markets. Naia’s founding team has the deep worldwide relationships with academia and industry required to identify relevant innovative drug development opportunities, and to effectively bring these new medicines to their respective regions. Naia is building a diverse portfolio of late-stage preclinical and clinical assets that address critical regional and global unmet medical needs.”

Omar Haffar PhD is a cell biologist with 28 years of experience in the biotechnology industry.

He is currently the founder, president and chief executive officer of Eos Biosciences Inc, a nanomedicines company based in Los Angeles. He began his career at Genentech, Inc and then worked at Bristol-Myers Squibb. He was co-founder and vice president of anti-infectives at Cytokine Networks and subsequently was founder and president of International Therapeutics, Inc. He served as managing director at Global Solutions for Infectious Diseases and was the principal founder, president and chief executive officer of Presidio Pharmaceuticals Inc. Dr Haffar serves on the Board of Directors of Eos Biosciences and Presidio Pharmaceuticals.

Dr Haffar received his B.S. in biology from the American University of Beirut in Lebanon and his MS in biology from the University of Oregon. He completed his PhD in physiology-anatomy at the University of California, Berkeley.

Robert Williamson III

Robert Williamson III

Naia Board of Directors

 

Robert F Williamson III is the CEO of privately held PharmAkea, a company involved in the development of fibrosis and oncology drugs, in addition to serving on the Naia Board of Directors.

Read More

“In the course of starting, managing and advising public and private biotech companies, I have observed what makes drug development companies successful. Companies need a sound strategy, a high quality pipeline, and a management team that has the experience to deliver value to the company’s shareholders and to patients. Naia has touched on each of these aspects: a unique model that allows financing and development flexibility, creating a robust portfolio of late-stage preclinical and clinical assets that will allow it to realize value quickly, inexpensively and at relatively low risk.”

Robert F Williamson III is the CEO of privately held PharmAkea, a fibrosis and oncology drug development company financed through a partnership with Celgene (NASDAQ: CELG). He has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers.

Previously, he helped finance and was a Director of Pharmasset, Inc. (NASDAQ: VRUS) which was bought by Gilead (NASDAQ:GILD) for $11B. He was also appointed to the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private company boards. Earlier, Mr Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology – which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc – which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT).

Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc, and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy.

Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, DC

He received a BA in Economics from Pomona College and an MBA from Stanford Graduate School of Business.

Evan Ng

Evan Ng

Partner: Dorsey & Whitney LLP
Secretary to the Board & General Counsel

 

Evan Ng is co-Chair of Dorsey & Whitney’s life sciences and health care practice, co-Chair of the firm’s Emerging Companies practice and the Department Head of the Northern California Corporate practice group.

Read More

Evan Ng is co-Chair of Dorsey & Whitney’s life sciences and health care practice, co-Chair of the firm’s Emerging Companies practice, and the Department Head of the Northern California Corporate practice group.

Evan has substantial experience representing public and private life science and technology companies across a broad range of matters that include venture capital and private equity financings, initial public offerings, mergers and acquisitions and strategic technology transactions.
In addition to maintaining an active specialty practice focused on the life science industry, Evan frequently advises underwriters on public offerings and private equity sponsors in the negotiation and execution of buyout transactions.

Evan also advises US companies and investors with respect to operations and investments in China, and is fluent in Cantonese and Mandarin.

Board of Advisors

Dr Jorge Puente MD

Chairman – Naia Board of Advisors

 

Dr Jorge Puente MD serves as chairman of Naia’s Board of Business Advisors. He has extensive experience in all areas of pharmaceutical development and financing and is also recognized internationally for his humanitarian work.

Read More

“Having worked across many operational areas of a large multinational pharmaceutical company including over 20 years deeply focused on clinical development, regulatory strategy and commercial needs of the Asian markets, I’m excited to join Naia’s Business Advisory Board. Naia’s plan to use an efficient operating process, a global strategy to develop drugs incorporating early input from key stakeholders will lead to the development of cost-effective, innovative therapeutic solutions that can address the local and global healthcare needs.”

Jorge Puente MD, serves as chairman of Naia’s Board of Business Advisors.

He is a co-founder and managing partner at Pleasanton Pharma Ventures, an investment firm founded in 2014 to invest in late-stage development programs. Prior to his current position, he was regional president, Asia Pacific and Canada, of Pfizer’s Oncology Business Unit responsible for operations in Japan, Australia, New Zealand, Canada and Korea. Prior to that, he held several positions of increasing responsibility at Pfizer including vice president, Medical and Regulatory Affairs, Japan and Asia Region; senior vice president and medical director, Pfizer – Japan; and medical director, Pfizer – China.

Early in his career, Dr. Puente was assistant professor of medicine at Mount Sinai Medical Center in New York, where he won the Solomon Benson Award for excellence in teaching medicine. Dr. Puente is recognized internationally for his humanitarian work. He organized the First World Congress on Post Traumatic Stress Disorder in Thailand after the tsunami in 2004 which resulted in numerous programs to aid those affected. He organized similar programs in Pakistan after the 2005 earthquake. In May 2013, Dr. Puente received “The Spirit of Asian American Award” from the Asian American Federation for his humanitarian work in Asia. Dr. Puente is a National Board Member of the Smithsonian.

Dr. Puente received his M.D. from SUNY Stony Brook and completed his postgraduate training at Mount Sinai Medical Center in New York.

Dr Ed Pezalla MD

Naia Board of Advisors

 

Dr Pezalla MD is a national and international public policy, public affairs and healthcare innovations leader who is active in helping inform and shape systems and policy frameworks in the US, in addition to serving on Naia’s Board of Advisors.

Read More

Dr Pezalla is a national and international public policy, public affairs and healthcare innovations leader with a unique understanding and perspective of patient, payer, health system provider and government needs. He is active in helping inform and shape systems and policy frameworks in the US through his activities at The Brookings/Engelberg Center, as an invited expert on reform of drug approval regulations for the President’s Council of Advisors on Science and Technology (PCAST) and as a planning board member for recommendations for the National Medical Device Surveillance System.

Dr Pezalla is currently vice president and national medical director for pharmaceutical policy and strategy at Aetna. He reports directly to the chief medical officer for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy-related issues and represents Aetna on industry work groups and conferences. Previously, Dr Pezalla was acting chief medical officer for Aetna’s operations in Doha, Qatar, where he managed the Qatari National Health Insurance scheme. He also served as chief clinical officer for Aetna Pharmacy Management. Prior to Aetna, he was vice president of clinical services for Prescription Solutions, a wholly-owned pharmacy benefits management subsidiary of United Health.

Dr Pezalla received his medical and undergraduate degrees from Georgetown University. He holds an MPH from the University of California at Berkeley.

Lord Edward (Tim) Razzall CBE

Naia Board of Advisors

 

Lord Razzall has more than 35 years of corporate finance experience in multinational and cross border transactions. He serves on numerous Boards and is currently the co-chairman of the Parliamentary Committee for Treasury matters in the UK.

Read More

Lord Razzall, a solicitor in the UK, has more than 35 years of corporate finance experience, particularly in multinational and cross border transactions.

He is currently a partner at RT Associates, a business advisory firm for growth companies in a variety of industries including healthcare. He is also chairman of the payment systems provider Boxhill Technologies PLC and director of the finance company Just Loans PLC.

Lord Razzall has had a long political career in the UK. Currently, he is the co-chairman of the Parliamentary Committee for Treasury matters. Previously, he held the post of Liberal Democrat Spokesperson for Trade and Industry/Business, Enterprise and Regulatory Reform. He was treasurer of the Liberal/Liberal Democratic Party after which he chaired the Liberal Democrats General Election Campaigns of 2001 and 2005.

Earlier in his career, he served as partner and chief executive at Frere Cholmeley Bischcoff.

Robert Williamson III

Naia Board of Advisors

 

Robert F Williamson III is the CEO of privately held PharmAkea, a company involved in the development of fibrosis and oncology drugs, in addition to serving on the Naia Board of Directors.

Read More

“In the course of starting, managing and advising public and private biotech companies, I have observed what makes drug development companies successful. Companies need a sound strategy, a high quality pipeline, and a management team that has the experience to deliver value to the company’s shareholders and to patients. Naia has touched on each of these aspects: a unique model that allows financing and development flexibility, creating a robust portfolio of late-stage preclinical and clinical assets that will allow it to realize value quickly, inexpensively and at relatively low risk.”

Robert F Williamson III is the CEO of privately held PharmAkea, a fibrosis and oncology drug development company financed through a partnership with Celgene (NASDAQ: CELG). He has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers.

Previously, he helped finance and was a Director of Pharmasset, Inc. (NASDAQ: VRUS) which was bought by Gilead (NASDAQ:GILD) for $11B. He was also appointed to the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private company boards. Earlier, Mr Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology – which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc – which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT).

Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc, and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy.

Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, DC

He received a BA in Economics from Pomona College and an MBA from Stanford Graduate School of Business.

Our Companies

We are building biotechnology companies that address unmet medical needs.

By creatively sourcing products for these companies and by financing and developing them globally, we aim to develop new products faster and more effectively than traditional biotech companies.

Naia’s first two companies are Naia Rare Diseases Inc and Naia Metabolic Inc and exemplify the types of company Naia is developing.

What We Do

Naia is funding and developing companies that address regional and global unmet medical needs in various markets with an initial focus on metabolic and rare diseases.

In selecting drug candidates, Naia focuses on those that have a potential impact on unmet medical need; and the scientific merit and ability to rapidly achieve clinical proof-of-concept while increasing asset value at lower risk and cost.

Naia operates its subsidiaries as a single organization for operating purposes, thus saving time and money in development.  Further savings are achieved by operating as a virtual company, using proven contract research organizations (CROs) and other contract organizations to manage its operations.

Using creative in-licensing and leveraging cross-border arbitrage (different regions value the same program differently), Naia is able to identify new opportunities quickly. The team’s worldwide network and Cayman Islands structure allows for programs to be developed and commercialized where they are most needed, creating instant arbitrage value.

While Naia targets drug development in emerging markets where the demand for branded drug opportunities is large, such as in the Middle East, Latin America and Asia Pacific, it also takes advantage of strategic opportunities in developed markets.

How We Do It

Naia’s unique operating structure allows implementation of a focused global strategy. This approach allows Naia to source, finance, develop and commercialize drugs efficiently and effectively.

Naia’s operating structure includes a Cayman Island-based holding company, a US based agent management company and several subsidiaries that focus on development activities of like assets.

This shared infrastructure and management team leads to increase efficiency in drug development at significant savings.

The holding companies have and will have operations in multiple locations, depending on market needs, including in Hong Kong, Ireland, Singapore, the United Kingdom and the United States.

Operating Structure

Naia’s unique operating structure allows implementation of a focused global strategy. This approach allows Naia to source, finance, develop and commercialize drugs efficiently and effectively.

Naia’s operating structure includes a Cayman Island-based holding company, a US based agent management company and several subsidiaries that focus on development activities of like assets.

This shared infrastructure and management team leads to increase efficiency in drug development at significant savings.

The holding companies have and will have operations in multiple locations, depending on market needs, including in Hong Kong, Ireland, Singapore, the United Kingdom and the United States.

  • Naia’s Global Advisory Network provides subsidiaries, access to the world’s leading scientific, medical and business advisors for advice, access and introductions.

 

  • Naia’s Cayman Islands-Based holding Company consolidates overhead costs across the model and allows seamless international transfer of intellectual property.

 

  • Naia’s Operating Entities are strategically located in targeted localities according to development needs.

Strategic Drug Development

Naia is pursuing niche regional opportunities for development and out-licensing of drug candidates to align with urgency on the part of local payers, health authorities and potential commercial partners, ensuring efficient, focused and cost-effective development.

For example, Naia will target regionally-specific commercial deals where the demand for branded drugs opportunities is large, such as in the Middle East, Latin America and Asia Pacific.

Naia can tailor an asset to a specific geography where the disease is prevalent and the unmet need is highest. Naia also will take advantage of strategic opportunities in developed markets.

Naia’s approach to identifying and selecting opportunities.

In selecting drug candidates, Naia focuses on those that have a potential impact on unmet medical need and the scientific merit and ability to rapidly achieve clinical proof-of-concept while increasing asset value at lower risk and cost.

Naia’s first two companies are Naia Rare Diseases and Naia Metabolic

Click image to visit Naia Rare Diseases website

Click image for more information

What the Experts are Saying

” … Knowing the individual backgrounds of the [Naia] management team, combined with the approach of the business model, it was immediately evident the right components where in place that could help Pharco to make a difference in emerging markets such as Egypt.”

Dr Sherine Helmy
CEO Pharco Pharmaceuticals

“Naia’s founding team has the deep worldwide relationships with academia and industry required to identify relevant innovative drug development opportunities, and to effectively bring these new medicines to their respective regions. Naia is building a diverse portfolio of late-stage preclinical and clinical assets that address critical regional and global unmet medical needs.”

Dr Omar Haffar
CEO EOS Biosciences

“Naia has … a unique model that allows financing and development flexibility, creating a robust portfolio of late-stage preclinical and clinical assets that will allow it to realize value quickly, inexpensively and at relatively low risk.”

Robert Williamson III
CEO PharmAkea

“Naia’s plan to use an efficient operating process, a global strategy to develop drugs incorporating early input from key stakeholders will lead to the development of cost-effective, innovative therapeutic solutions that can address the local and global healthcare needs.”

Dr Jorge Puente MD
Managing Partner at Pleasanton Pharma Ventures

“Naia’s management team has shown both passion and urgency to help the medical community advance and clinically evaluate a potentially life-changing new treatment for this incurable disease [Short Bowel Syndrome].”

Dr Mark Pimentel MD
Professor of Medicine and Director of the Gastrointestinal Motility Program
Cedars-Sinai Medical Center, Los Angeles

Latest Naia News

Naia Rare Diseases Announces UK Clinical Trial Authorisation for NB 1001 for Short Bowel Syndrome – Nov 15 2017

Naia Rare Diseases today announced that it has received Clinical Trial Authorisation from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.

Naia Rare Diseases Secures Investment from Cedars-Sinai Health System

Naia Rare Diseases today announced that Cedars-Sinai will participate on its ongoing Series B financing round.

Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome

Naia Rare Diseases today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b clinical trial for its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.

Naia Rare Diseases to Present at 28th Annual ROTH Capital Conference

Naia Rare Diseases today announced that it will be presenting at the 28th Annual ROTH Capital Conference on Tuesday, March 15, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California.

Naia Rare Diseases appoints Professor Palle Bekker Jeppesen to its Scientific Advisory Board

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has appointed Professor Palle Bekker Jeppesen, MD, Head of Research at the Department of Gastroenterology, Rigshospitalet, Copenhagen, to its Scientific Advisory Board.

Naia Rare Diseases Forms Scientific Advisory Board Comprised of Internationally Renowned Experts and Scientists

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has formed a Scientific Advisory Board (SAB) comprised of internationally renowned experts and scientists in gastrointestinal diseases, particularly Short Bowel Syndrome (SBS).

Naia Rare Diseases granted orphan drug designation for NB1001

Naia Limited today announced that its subsidiary, Naia Rare Diseases, has been granted by the U.S. Food and Drug Administration (FDA) orphan drug designation for NB1001, its long-acting GLP-1 receptor agonist, for the treatment of Short Bowel Syndrome (SBS).

Naia Limited Successfully Completes Pre-IND Meeting with US FDA for NB1001

Naia Limited, an international drug development company with an initial portfolio of innovative, clinical-stage compounds for short bowel syndrome, NASH and Type 2 diabetes, today announced that its subsidiary, Naia Rare Diseases, Inc. successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA).

Contact us for further information